Microporous polysaccharide hemosphere absorbable hemostat use in cardiothoracic surgical procedures

Journal of Cardiothoracic Surgery

Matthias Loebe¹  Michael J Reardon¹  Uy Q Ngo¹  Erik E Suarez¹  Limael Rodriguez¹  Lance N Blau¹  Brian A Bruckner¹ 

[1] Houston Methodist Hospital, Methodist DeBakey Heart & Vascular Center, Houston, TX, USA

关键词: Coagulants;    Biomaterials;    Bleeding control;   

Others  :  1152210
DOI  :  10.1186/s13019-014-0134-4

 received in 2014-04-08, accepted in 2014-07-17,  发布年份 2014

【 摘 要 】

Background

Topical hemostatic agents are used to reduce bleeding and transfusion need during cardiothoracic surgery. We report our experience with Arista® AH Absorbable Hemostatic Particles (Arista® AH), a novel plant-based microporous polysaccharide hemostatic powder.

Methods

Data were retrospectively collected for patients (n = 240) that received cardiothoracic surgery at our institution from January 2009 to January 2013 with (n = 103) or without (n = 137) the use of Arista® AH. Endpoints included protamine to skin closure time (hemostasis time), cardiopulmonary bypass time, quantity of Arista® AH applied, intraoperative blood product usage, intraoperative blood loss, chest tube output 48 hours postoperatively, blood products required 48 hours postoperatively, length of stay in the intensive care unit, 30-day morbidity, and 30-day mortality.

Results

240 patients (176 M: 64 F) underwent 240 cardiothoracic procedures including heart transplantation (n = 53), cardiac assist devices (n = 113), coronary artery bypass grafts (n = 20), valve procedures (n = 19), lung transplantation (n = 17), aortic dissection (n = 8), and other (n = 10). Application of Arista® AH led to significant reduction in hemostasis time versus the untreated control group (Arista® AH: 93.4 ± 41 min. vs. Control: 107.6 ± 56 min., p = 0.02). Postoperative chest tube output in the first 48 hours was also significantly reduced (Arista® AH: 1594 ± 949 mL vs. Control: 2112 ± 1437 mL, p < 0.001), as well as transfusion of packed red blood cells (Arista® AH: 2.4 ± 2.5 units vs. Control: 4.0 ± 5.1 units, p < 0.001). There was no significant difference in 30-day mortality or postoperative complications.

Conclusion

Use of Arista® AH in complex cardiothoracic surgery resulted in a significant reduction in hemostasis time, postoperative chest tube output, and need for postoperative blood transfusion.

【 授权许可】

   
2014 Bruckner et al.; licensee BioMed Central

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Levy JH, Despotis GJ: Transfusion and hemostasis in cardiac surgery. Transfusion 2008, 48(1):1S.
• [2]Hall T, Sines J, Spotnitz A: Hemorrhage related reexploration following open heart surgery: the impact of pre-operative and post-operative coagulation testing. Cardiovasc Surg 2002, 10(2):146-153.
• [3]Gorlinger K, Shore-Lesserson L, Dirkmann D, Hanke AA, Rahe-Meyer N, Tanaka KA: Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth 2013, 27(4):20-34.
• [4]LaPar D, Crosby I, Ailawadi G, GAd N, Choi E, Spiess BD, Rich JB, Kasirajan V, Fonner E Jr, Kron IL, Speir AM: Blood product conservation is associated with improved outcomes and reduced costs after cardiac surgery. J Thorac Cardiovasc Surg 2013, 145(3):796-803.
• [5]Valentine R, Wormald P, Sindwani R: Advances in absorbable biomaterials and nasal packing. Otolaryngol Clin N Am 2009, 42:813-828.
• [6]Barnard J, Millner R: A review of topical hemostatic agents for use in cardiac surgery. Ann Thorac Surg 2009, 88:1377-1383.
• [7]Emmert M, Salzberg S, Theusinger OM, Felix C, Plass A, Hoerstrup SP, Falk V, Gruenenfelder J: How good patient blood management leads to excellent outcomes in Jehovah’s witness patients undergoing cardiac surgery. Interact Cardiovasc Thorac Surg 2011, 12(2):183-188.
• [8]Christensen M, Krapf S, Kempel A, Avon Heymann C: Costs of excessive postoperative hemorrhage in cardiac surgery. J Thorac Cardiovasc Surg 2009, 138(3):687-693.
• [9]Tschan C, Nie M, Schwandt E, Oertel J: Safety and efficacy of microporous polysaccharide hemospheres in neurosurgery. Neurosurgery 2011, 69(1):49-63.
• [10]Hamdi G, Ponchel G: Enzymatic degradation of epichlorohydrin crosslinked starch microspheres by alpha-amylase. Pharm Res 1999, 16:867.
• [11]Dong Y, Schrader L, Drake J: Hemostatic dose response of degradable starch microspheres (DSM45) as measured by thromboelastography.Presented at: Network for Advancement of Transfusion Alternatives 2nd Annual Symposium 2001, Berlin, Germany.
• [12]Oz M, Cosgrove D III, Badduke B, Hill JD, Flannery MR, Palumbo R, Topic N: Controlled clinical trial of a novel hemostatic agent in cardiac surgery. Ann Thorac Surg 2000, 69:1376-1382.
• [13]Nasso G, Piancone F, Bonifazi R, Romano V, Visicchio G, De Filippo CM, Impiombato B, Fiore F, Bartolomucci F, Alessandrini F, Speziale G: Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg 2009, 88(5):1520.
• [14]Rajagopal P, Hakim N: The use of a powdered polysaccharide hemostat in live donor nephrectomies controls bleeding and reduces postoperative complications. Transplant Proc 2011, 43:424-426.
• [15]Nunez-Nateras R, Hurd K, Ferrigni E, Castle EP, Andrews PE, Humphreys MR: Athermal nerve sparing robot-assisted radical prostatectomy: initial experience with microporous polysaccharide hemospheres as a topical hemostativ agent. World J Urol 2011, 31(3):523-527.
• [16]Antisdel J, West-Denning J, Sindwani R: Effect of microporous polysaccharide hemispheres (MPH) on bleeding after endoscopic sinus surgery: randomized control study. Otolaryngology- Head and Neck Surgery 2009, 141:353-357.
• [17]Sindwani R: Use of novel hemostatic powder MPH for endoscopic sinus surgery: initial impressions. Otolaryngology- Head and Neck Surgery 2009, 140:262-263.